Announced preliminary results of Phase I clinical trial of the antibody-inducing peptide FPP004X. Good safety profile, confirmed increase in anti-IgE antibody levels. Future development plans to be discussed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4881","jir_company_name":"FanPep Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-07-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4881-20260727-01.pdf","jir_short_summary":"Announced preliminary results of Phase I clinical trial of the antibody-inducing peptide FPP004X. Good safety profile, confirmed increase in anti-IgE antibody levels. Future development plans to be discussed.","jir_summary":"### Overview of the Clinical Trial\nFanPep Co., Ltd. announced preliminary results of a Phase I clinical trial of the antibody-inducing peptide FPP004X for hay fever. The study evaluated safety and immunogenicity across multiple dosing cohorts in healthy adults and hay fever patients. Safety was excellent with no discontinuations due to side effects or adverse events. An increase in anti-IgE antibody levels was also observed, indicating immune response. No symptom improvement was noted after exposure to cedar pollen. Moving forward, discussions with Shionogi & Co., Ltd. will determine the future development strategy.\n\n### Future Outlook and Corporate Activities\nThe results of this trial will not impact the financial results for the fiscal year ending December 2026. FanPep is partnering with Shionogi & Co., Ltd. to develop and commercialize FPP004X globally. Details regarding further clinical development and partnership agreements will continue to be disclosed.","jir_financial_highlights":"Positive rate of anti-IgE antibodies: Part 1: 97% (35\/36 cases), Part 2: 100% (24\/24 cases) (Unknown)\nIncidence of adverse reactions: No clinical issues aside from local and systemic reactions (Unknown)\nCases of discontinuation due to adverse events: None observed (Unknown)","jir_category":"","jir_hashtags":"#FanPep, #ClinicalTrial, #JapanStocks","jir_key_figures":"Positive rate of anti-IgE antibodies: Part 1 97% (35\/36 cases), Part 2 100% (24\/24 cases)\nIncidence of adverse reactions: No clinical issues aside from local and systemic reactions\nDiscontinuation due to adverse events: None","jir_meta_title":"\u3010FanPep\u3011Clinical Trial Milestone for Antibody-Inducing Peptide | July 2026","jir_meta_description":"FanPep Co., Ltd. announced preliminary results from the Phase I clinical trial of the hay fever treatment FPP004X. Good safety and immunogenicity confirmed; future development plans to be discussed.","jir_og_title":"\u3010FanPep\u3011Clinical Trial Milestone for Antibody-Inducing Peptide | July 2026","jir_og_description":"FanPep announced clinical trial results for hay fever treatment. Safety and immunogenicity confirmed, and discussions on future development are underway.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60651,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88479","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n